Overview

Autologous Transplant for Multiple Myeloma

Status:
Completed

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Cyclophosphamide
Lenograstim
Melphalan
Mesna
Sargramostim